LuciAsc
Original price was: $1,500.00.$1,237.33Current price is: $1,237.33.
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).
In Stock
Description
COMPOSITION:
Each LuciAsc tablet contains: 43.24mg Asciminib HCL equivalent to Asciminib ………… 40mg
INDICATION:
LuciAsc is a kinase inhibitor indicated for the treatment of adult patients with:
· Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).
· Ph+ CML in CP Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation.
DOSAGE AND USE:
· Recommended Dosage in Ph+ CML in CP: 80 mg orally once daily or 40 mg twice daily.
· Recommended Dosage in Ph+ CML in CP with the T315I Mutation: 200 mg orally twice daily.
Avoid food for at least 2 hours before and 1 hour after taking LuciAsc. Tablet should be swallowed whole & not chewed or crushed.
STORAGE:
in a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING:
Keep medicine out of reach of Children. Do not administered LuciAsc in Pregnancy and Lactation patient treatment.
Reviews
There are no reviews yet.